Pharmaceutical

Health Canada approves AstraZeneca-Merck’s prostate cancer therapy

AstraZeneca and Merck have received conditional approval from Health Canada for Lynparza (olaparib) combination to treat prostate cancer.

Jul 15, 2023 - 20:00
Health Canada approves AstraZeneca-Merck’s prostate cancer therapy
AstraZeneca and Merck have received conditional approval from Health Canada for Lynparza (olaparib) combination to treat prostate cancer.
Read the original article

Tags:

Previous Article

Gilead, CHAI and Penta to enhance HIV treatment for children

Next Article

Emmaus gains marketing authorisation for sickle cell treatment in Oman

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

23andMe breach targeted Chinese, Jewish populations

23andMe breach targeted Chinese, Jewish populations

Jan 30, 2024

Partnership deals for psychedelic drugs take a trip with 500% surge in 2023

Partnership deals for psychedelic drugs take a trip wit...

Dec 2, 2023

NICE recommends Boehringer’s tenecteplase for NHS stroke care

NICE recommends Boehringer’s tenecteplase for NHS strok...

Jul 26, 2024